Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity

Basit Öğe Kaydı
dc.contributor.authorKurtipek, Gulcan Saylam
dc.contributor.authorKesli, Recep
dc.contributor.authorAkyurek, Fatma Tuncez
dc.contributor.authorAkyuret, Fikret
dc.contributor.authorTerzi, Yuksel
dc.date.accessioned2020-03-26T19:06:40Z
dc.date.available2020-03-26T19:06:40Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective: Psoriasis is a chronic, relapsing, inflammatory, hyper-proliferative skin disease. Plasma-soluble urokinase plasminogen activator receptor (suPAR) is released from the cell membrane-bound plasminogen activator and is a new biomarker of systemic inflammation. The aim of this study is to investigate plasma levels in psoriasis patients and determine their correlation with the Psoriasis Area and Severity Index (PASI) score. Materials and methods: The plasma suPAR levels of 50 healthy individuals and 65 psoriasis patients were measured using the Micro-ELISA method and the relation with PASI was investigated. Results: On comparing plasma suPAR levels of the psoriasis patients with the control group consisting of healthy individuals, no statistically significant difference was determined (5.29 ng/ml +/- 2.12 and 6.03 ng/ml +/- 2.42, respectively, p = 0.326; Table 1). Likewise, there was no significant correlation between the suPAR levels and PASI score (r = 0.147, p = 0.243 > 0.05). Conclusions: There was no statistically significant difference in the plasma SuPAR levels of psoriasis patients compared to the control group. Nevertheless, we firmly believe that plasma SuPAR, a new biomarker, could indicate disease severity if conducted with larger patient series and with moderate to severe psoriasis patients.en_US
dc.description.sponsorshipKonya Education and Research Hospital Research Funden_US
dc.description.sponsorshipThis study was financially supported by the Konya Education and Research Hospital Research Fund.en_US
dc.identifier.doi10.15570/actaapa.2015.19en_US
dc.identifier.endpage75en_US
dc.identifier.issn1318-4458en_US
dc.identifier.issn1581-2979en_US
dc.identifier.issue4en_US
dc.identifier.pmid26697731en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage73en_US
dc.identifier.urihttps://dx.doi.org/10.15570/actaapa.2015.19
dc.identifier.urihttps://hdl.handle.net/20.500.12395/32436
dc.identifier.volume24en_US
dc.identifier.wosWOS:000420882100004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherDERMATOVENEROLOGICAL SOC SLOVENIAen_US
dc.relation.ispartofACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICAen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectpsoriasisen_US
dc.subjectsuPARen_US
dc.subjectPASIen_US
dc.titlePlasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu